Venus Remedies Limited has further consolidated its position in the Guff Cooperation Council (GCC), Association of South East Asian Nations (ASEAN), Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnja and Trinidaid & Tobago for key chemotherapy drugs. With this, the company has secured 503 marketing approvals for its oncology products across 75 countries. While Venus Remedies has secured marketing approval for pemetrexed from Malaysia, one of the markets in the ASEAN region, it has reached important regulatory milestones with product registration for docetaxel in Oman, gemcitabine in Bosnia and carboplatin, bortezomib and docetaxel in Trinidid & Tobago.

Terming the development as another important step towards achieving the company's goal of emerging as the top oncology medicine supplier from India in the ASEAN region and further expanding the reach of its oncology products in the GCC, Balkan and Caribbean regions.